USD0.000æéå€ååŒÂ  (ET)
18.09MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
11.430å§å€
12.787é«å€
97.23Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
6.05%売買å転ç
11.620忥çµå€
11.150å®å€
724.70K売買代é
æå€±é¡æ ªäŸ¡åçç
0.86PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
--ç·è³ç£å©çç
18.20052é±é«å€
1.19åºæ¥é«æ¯ç%
-1.60MçŽå©ç
1.61Mæ ªåŒæ°
-4.90171æ ªåœããå©çïŒEPSïŒ
--ããŒã¿å€
--èªå·±è³æ¬å©çç
2.88052é±å®å€
14.09%æ¯ãå¹
--ç²å©çç
18.09MæäŸ¡ç·é¡
-2.19ãªã¹ã¯ãªã¿ãŒã³
7.21%ãªã¹ã¯ç
Polyrizon Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
ææšî
ææš
売ã(4)
äžç«(1)
è²·ã(0)
ç§»åå¹³å
売ã(6)
äžç«(0)
è²·ã(0)
Polyrizon Ltdã®äŒæ¥æ
å ±î
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
äŒæ¥ã³ãŒãPLRZ
äŒæ¥åPolyrizon Ltd
æé«çµå¶è²¬ä»»è
ãCEOãIzraeli (Tomer)
ãŠã§ããµã€ãhttps://polyrizon-biotech.com/
æ ªäž»çµ±èšî
ãããã質å
Polyrizon LtdïŒPLRZïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îPolyrizon LtdïŒPLRZïŒã®çŸåšã®æ ªäŸ¡ã¯11.21ã§ãã
Polyrizon Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îPolyrizon Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯PLRZã§ãã
Polyrizon Ltdã®52é±é«å€ã¯ãããã§ããïŒ
îPolyrizon Ltdã®52é±é«å€ã¯18.20ã§ãã
Polyrizon Ltdã®52é±å®å€ã¯ãããã§ããïŒ
îPolyrizon Ltdã®52é±å®å€ã¯2.88ã§ãã
Polyrizon Ltdã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îPolyrizon Ltdã®æäŸ¡ç·é¡ã¯18.03Mã§ãã
Polyrizon Ltd (PLRZ) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îPolyrizon LtdïŒPLRZïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-4.90ã§ãã